SCLL signs agreement to provide research and assay services in support of Agennix's talactoferrin program

Download PDF Copy

Editorial Checklist

Reviewed

Stem Cell Innovations, Inc.Mar 3 2010

NewsGuard 100/100 Score

Stem Cell Innovations (Pink Sheets: SCLL) announced today that the Company has signed a Master Services Agreement to provide research and assay services in support of Agennix's talactoferrin program. The assay utilizes SCLL's C3A human liver cell line.

"We are happy to enter into this contract with Agennix," said James H. Kelly, PhD, CEO of Stem Cell Innovations. "Our C3A cells provide a reliable and reproducible foundation on which to base the talactoferrin assays."

In addition to the talactoferrin assays, SCLL will provide other research and cell culture services to Agennix.

Source:

Stem Cell Innovations, Inc.

Posted in: Device / Technology News

Tags: Assay, B Cell, Cancer, Cell, Cell Culture, Cell Line, Exosomes, Liver, Lung Cancer, Non-Small Cell Lung Cancer, Research, Sepsis, Small Cell Lung Cancer, Stem Cells, T-Cell, Toxicology

Comments (0)

Download PDF Copy

Suggested Reading

Research links COVID-19 vaccines to temporary facial palsy in over 5,000 patients

Research links COVID-19 vaccines to temporary facial palsy in over 5,000 patients

The potential to optimize laboratory testing and operations with automation and AI

The potential to optimize laboratory testing and operations with automation and AI

Patient-derived organoids: Transforming cancer research and personalized medicine

Patient-derived organoids: Transforming cancer research and personalized medicine

New research explores how antimicrobial exposure affects Parkinson’s disease risk

New research explores how antimicrobial exposure affects Parkinson’s disease risk

Research shows brain synchronization between humans and dogs

Research shows brain synchronization between humans and dogs

BMI's influence on disease pathogenesis uncovered in new research

BMI's influence on disease pathogenesis uncovered in new research

Research suggests no need for yellow fever vaccine booster after initial dose

Research suggests no need for yellow fever vaccine booster after initial dose

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Antibiotic activity altered by interaction with nanoplastics, new research shows